Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP

M. Desrosiers, L. P. Mannent, N. Amin, G. W. Canonica, P. W. Hellings, P. Gevaert, J. Mullol, S. E. Lee, S. Fujieda, J. K. Han, C. Hopkins, W. Fokkens, R. Jankowski, S. H. Cho, X. Mao, M. Zhang, M. S. Rice, A. H. Khan, S. Kamat, N. PatelN. M.H. Graham, M. Ruddy, C. Bachert

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2-mediated inflammation. We report results of pooled analyses from 2 randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24 [NCT02912468]; SINUS-52 [NCT02898454]) to evaluate dupilumab effect versus placebo in adults with CRSwNP with/without SCS use and sinonasal surgery. Methodology: SINUS-24 patients were randomised 1:1 to subcutaneous dupilumab 300 mg (n=143) or placebo (n=133) every 2 weeks (q2w) for 24 weeks. SINUS-52 patients were randomised 1:1:1 to 52 weeks of subcutaneous dupilumab 300 mg q2w (n=150), 24 weeks q2w followed by 28 weeks of dupilumab 300 mg every 4 weeks (n=145) or 52 weeks of placebo q2w (n=153). Results: Dupilumab reduced the number of patients undergoing sinonasal surgery (82.6%), the need for in-study SCS use (73.9%), and SCS courses (75.3%). Significant improvements were observed with dupilumab vs placebo regardless of prior sinonasal sur gery or SCS use in nasal polyp, nasal congestion, Lund-MacKay, and Sinonasal Outcome Test (22-items) scores, and the University of Pennsylvania Smell Identification Test. Conclusions: Dupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sinonasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior sinonasal surgery.

Original languageEnglish
Pages (from-to)301-311
Number of pages11
Issue number3
StatePublished - 2021


  • Nasal polyps
  • Paranasal sinus diseases
  • Rhinitis
  • Sinusitis


Dive into the research topics of 'Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP'. Together they form a unique fingerprint.

Cite this